Sulfonylurea Therapy Benefits Neurological and Psychomotor Functions in Patients With Neonatal Diabetes Owing to Potassium Channel Mutations
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Neonatal diabetes secondary to mutations in potassium-channel subunits is a rare disease but constitutes a paradigm for personalized genetics-based medicine, as replacing the historical treatment with insulin injections with oral sulfonylurea (SU) therapy has been proven beneficial. SU receptors are widely expressed in the brain, and we therefore evaluated potential effects of SU on neurodevelopmental parameters, which are known to be unresponsive to insulin. RESEARCH DESIGN AND METHODS: We conducted a prospective single-center study. Nineteen patients (15 boys aged 0.1–18.5 years) were switched from insulin to SU therapy. MRI was performed at baseline. Before and 6 or 12 months after the switch, patients underwent quantitative neurological and developmental assessments and electrophysiological nerve and muscle testing. RESULTS: At baseline, hypotonia, deficiencies in gesture conception or realization, and attention disorders were common. SU improved HbA1c levels (median change −1.55% [range −3.8 to 0.1]; P < 0.0001), intelligence scores, hypotonia (in 12 of 15 patients), visual attention deficits (in 10 of 13 patients), gross and fine motor skills (in all patients younger than 4 years old), and gesture conception and realization (in 5 of 8 older patients). Electrophysiological muscle and nerve tests were normal. Cerebral MRI at baseline showed lesions in 12 patients, suggesting that the impairments were central in origin. CONCLUSIONS: SU therapy in neonatal diabetes secondary to mutations in potassium-channel subunits produces measurable improvements in neuropsychomotor impairments, which are greater in younger patients. An early genetic diagnosis should always be made, allowing for a rapid switch to SU.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gloyn, A. L., Pearson, E. R., Antcliff, J. F., Proks, P., Bruining, G. J., Slingerland, A. S., Howard, N., Srinivasan, S., Silva, J. M. C. L., Molnes, J., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032922 · Cited by 1,137
Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations
Pearson, E. R., Flechtner, I., Njølstad, P. R., Malecki, M. T., Flanagan, S. E., Larkin, B., Ashcroft, F. M., Klimes, I., Codner, E., Iotova, V., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061759 · Cited by 988
Self-citationActivating Mutations in the ABCC8 Gene in Neonatal Diabetes Mellitus
Babenko, A. P., Polak, M., Cavé, H., Busiah, K., Czernichow, P., Scharfmann, R., Bryan, J., Aguilar-Bryan, L., Vaxillaire, M., & Froguel, P. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055068 · Cited by 655
Self-citation
Cited by
Hattersley, A. T., Greeley, S. A. W., Polak, M., Rubio-Cabezas, O., Njølstad, P. R., Mlynarski, W., Castano, L., Carlsson, A., Raile, K., Chi, D. V., et al. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12772 · Cited by 319
“deficit hyperactivity disorder, anxiety disorder, or autism, and/or had behavioral or sleep difficulties (51, 68-71).”
Self-citationPrecision diabetes: learning from monogenic diabetes
Hattersley, A. T., & Patel, K. A. (2017) · Diabetologia · doi:10.1007/s00125-017-4226-2 · Cited by 306
New insights into KATP channel gene mutations and neonatal diabetes mellitus
Pipatpolkai, T., Usher, S., Stansfeld, P. J., & Ashcroft, F. M. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0351-y · Cited by 122
Neonatal Diabetes and the K ATP Channel: From Mutation to Therapy
Ashcroft, F. M., Puljung, M. C., & Vedovato, N. (2017) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2017.02.003 · Cited by 106
Metadata
- Authors
- Beltrand, J., Elie, C., Busiah, K., Fournier, E., Boddaert, N., Bahi-Buisson, N., Vera, M., Bui-Quoc, E., Ingster-Moati, I., Berdugo, M., Simon, A., Gozalo, C., Djerada, Z., Flechtner, I., Treluyer, J.-M., Scharfmann, R., Cavé, H., Vaivre-Douret, L., Polak, M., & on behalf of the GlidKir Study Group
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2015-10-05
- Volume
- 38
- Issue
- 11
- Pages
- 2033-2041
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2177721863
- Cited by
- 98
- References
- 3
- FWCI
- 10.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sulfonylurea Therapy Benefits Neurological and Psychomotor Functions in Patients With Neonatal Diabetes Owing to Potassium Channel Mutations. https://app.cochat.ai/papers/10.2337/dc15-0837
- The paper
- Beltrand, J., Elie, C., Busiah, K., Fournier, E., Boddaert, N., Bahi-Buisson, N., Vera, M., Bui-Quoc, E., Ingster-Moati, I., Berdugo, M., Simon, A., Gozalo, C., Djerada, Z., Flechtner, I., Treluyer, J.-M., Scharfmann, R., Cavé, H., Vaivre-Douret, L., Polak, M., & on behalf of the GlidKir Study Group. (2015). Sulfonylurea Therapy Benefits Neurological and Psychomotor Functions in Patients With Neonatal Diabetes Owing to Potassium Channel Mutations. Diabetes Care. https://doi.org/10.2337/dc15-0837
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.